brain
The OrganaBio Blog

Priya Baraniak, Ph.D.

Priya Baraniak, Ph.D.
Dr. Baraniak is a proven strategic thinker, problem solver and leader who brings 20 years of expertise in stem cells and tissue engineering, coupled with a keen business acumen, to OrganaBio. Dr. Baraniak has published multiple peer-reviewed papers and book chapters on the use of stem cells and biomaterials in cardiac repair and regeneration and is routinely invited to speak at conferences.

Recent Posts

Developing a Robust CGT Manufacturing Process

Posted by Priya Baraniak, Ph.D. on October 28, 2020

In this presentation, OrganaBio's Head of Process & Product Development highlights our approach to setting the stage early in process development for sustained manufacturing success. This talk was originally given at the 2020 Cell & Gene Therapy Bioprocessing & Commercialization global conference. The conference brought together 856 members of the cell and gene therapy community in an effort to stimulate collaborations and partnerships that accelerate the development of life-saving or life-altering therapies for patients in need.

Read More
0 Comments // View or add comments

Topics: Allogeneic Cell Therapy, cGMP Manufacturing, Uncategorized

Who We Are

Posted by Priya Baraniak, Ph.D. on May 22, 2020

OrganaBio was founded in 2018 by scientists and business leaders motivated to bring next generation regenerative medicine therapies to market. Since then, we have assembled a team of 16 industry veterans, from scientists and engineers with years of bioprocess and therapeutic development experience to those versed in Quality Assurance, Quality Control, Regulatory Affairs and successful business-building. Combined, we have over two centuries of experience in all areas necessary for success in regenerative medicine! Our team is passionate about expediting the development of novel cell and gene therapies, ultimately improving quality of life and/or saving lives for many. We truly believe that regenerative medicine is the future of medicine, and we work relentlessly to help our customers and partners bring their therapies to market.

Read More
0 Comments // View or add comments

Topics: OrganaBio

Why We Do It

Posted by Priya Baraniak, Ph.D. on May 21, 2020

At OrganaBio, we believe that nothing truly worthwhile is easy…. But we can make it easier for our partners and customers. That’s why we set out to take on a significant challenge – to alleviate bottlenecks in raw material supply and expand the limited options for cGMP manufacturing that are keeping the regenerative medicine industry from reaching its full potential. It’s no news that cell and gene therapy have witnessed substantial growth over the last decade, with the pace of innovation only continuing to accelerate. The headlines yield promising news week after week. Numerous cellular therapies are currently in clinical development, using a variety of cell types. Companies and organizations are increasingly investing money, time, and effort in this space. The engine of unprecedented therapeutic change is churning, but does the industry have the fuel to supply such growth? We want to ensure the answer is a resounding “Yes” – This is why we do it.

Read More
0 Comments // View or add comments

Topics: OrganaBio

Add a Comment